The CCSG senior leadership includes the MD Anderson president and principal investigator. Dr. Ronald A. DePinho, the provost and executive vice president ad interim. Dr. Thomas Buchholz, the vice president for translational research and co-principal investigator. Dr. Robert Bast, the vice president for basic science and associate director for basic science. Dr. Mien-Chie Hung, the vice president for clinical research administration and associate director for clinical research. Dr. Aman Buzdar, the Vice President for Cancer Prevention and associate director for cancer prevention. Dr. Ernest Hawk, and the chair of the Department of Health Disparities Research and associate director for health disparities Dr. David Wetter. This leadership team comprises the CCSG Executive Committee. Dr. DePinho as president of MD Anderson has authority over all aspects of the institution, providing vision and ultimate oversight for all clinical, research, education, and prevention activities. Dr. DePinho also chairs the MD Anderson institutional executive committee providing leadership and strategic direction in support of MD Anderson's mission and vision. Dr. Buchholz provides executive leadership for the development of all research and academic activities. Dr. Bast meets with program leaders, reviews program membership, encourages program activities, promotes multidisciplinary grants, coordinates the physician-scientist and clinician-investigator programs, meets with shared resource directors, reviews capital equipment requests, oversees finances of the core facilities, helps to develop new shared resources, and recommends use of development funds. Dr. Hung is responsible for facilitating all aspects of basic research and strengthening the intraprogrammatic- and interprogrammatic collaborations of the basic science programs. Dr. Buzdar is responsible for clinical research infrastructure, facilitates all aspects of clinical research and ensures that MD Anderson adheres to the highest standards of clinical research compliance with federal regulations. Dr. Hawk provides strategic and tactical direction to the center's work in cancer prevention research, education, and clinical services, and helped to establish the institution's cancer control program to guide policy, educational, and service initiatives oriented toward community needs. Dr. Wetter coordinates efforts to assure minority participation in clinical trials working with other members of the administration to increase the number of minority patients cared for at MD Anderson.

Public Health Relevance

The senior leadership of the CCSG mirrors the senior leadership of the institution as a whole and provides representation across the research spectrum from basic to translational, clinical and population based research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759807
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$307,358
Indirect Cost
$115,339
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Hui, David; Hess, Kenneth; Dibaj, Seyedeh S et al. (2018) The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer 124:2246-2252
LeBleu, Valerie S; Kalluri, Raghu (2018) A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 11:
Liu, Yang; Sethi, Nilay S; Hinoue, Toshinori et al. (2018) Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33:721-735.e8
Saintigny, Pierre; Mitani, Yoshitsugu; Pytynia, Kristen B et al. (2018) Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124:3693-3705
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Saltz, Joel; Gupta, Rajarsi; Hou, Le et al. (2018) Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23:181-193.e7
Dondossola, Eleonora; Alexander, Stephanie; Holzapfel, Boris M et al. (2018) Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med 10:
Yue, Jinbo; Shi, Qiuling; Xu, Ting et al. (2018) Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res 27:1563-1570
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Nguyen, Tuan M; Kabotyanski, Elena B; Dou, Yongchao et al. (2018) FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation. Cancer Res 78:4229-4240

Showing the most recent 10 out of 12418 publications